Lyell Immunopharma Income Statement (2019-2026) | LYEL

Income Statement Dec2019 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
2.63M2.75M2.82M0.55M35.74M0.00M48.39M0.07M0.03M0.03M0.01M0.00M0.01M0.03M0.01M0.01M0.01M0.01M0.01M0.00M
Operating items
Research & Development (Quarter)
46.45M31.43M19.29M35.83M43.72M41.61M38.03M44.63M47.47M43.85M46.99M43.17M40.26M39.50M48.67M43.45M34.86M28.17M52.20M36.60M
Selling, General & Administrative (Quarter)
19.11M21.24M31.87M34.42M30.45M26.08M26.35M19.28M19.03M15.51M13.17M13.49M12.26M11.77M14.52M14.05M9.79M10.69M10.62M9.55M
Other Operating Expenses (Quarter)
0.22M0.76M0.80M1.12M1.17M1.25M1.21M1.29M0.57M0.29M0.64M1.09M0.98M0.73M0.51M0.12M-1.06M1.59M1.50M1.90M
Operating Expenses (Quarter)
65.33M51.92M50.36M69.13M73.00M66.44M63.17M62.62M65.93M59.06M59.52M55.58M51.54M50.54M201.16M57.37M47.15M37.27M127.65M44.26M
Operating Income (Quarter)
-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M
EBIT (Quarter)
-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M
Non-operating items
Interest & Investment Income (Quarter)
0.22M0.27M0.32M0.40M0.95M2.25M3.45M4.50M5.26M6.61M7.08M6.82M6.36M5.96M4.92M3.86M3.28M3.27M2.68M2.19M
Other Non Operating Income (Quarter)
-0.11M0.02M-0.04M0.04M-0.01M-1.07M2.93M1.10M-0.33M1.58M-0.51M1.09M-0.65M-0.04M4.29M1.31M1.18M-4.86M-15.76M17.91M
Non Operating Income (Quarter)
0.11M0.29M-0.04M0.04M0.94M-3.82M4.99M1.10M2.02M8.19M-0.51M1.09M5.72M-0.04M-1.85M5.17M1.18M-4.86M-2.67M17.91M
Net income details
EBT (Quarter)
-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M
Profit After Tax (Quarter)
-62.59M-48.88M-83.71M-68.14M-36.32M-70.25M-8.40M-66.96M-63.89M-50.85M-52.93M-60.67M-45.81M-44.58M-191.94M-52.20M-42.68M-38.85M-140.72M-24.15M
Income from Continuing Operations (Quarter)
-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M
Consolidated Net Income (Quarter)
-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M
Income towards Parent Company (Quarter)
-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M
Net Income towards Common Stockholders (Quarter)
-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M
Additional items
EPS (Basic) (Quarter)
-1.47-0.20-0.18-0.28-0.15-0.28-0.03-0.27-0.26-0.20-17.97-0.24-3.59-3.48-14.40-3.54-2.89-2.13-7.68-1.10
EPS (Weighted Average and Diluted) (Quarter)
-1.47-0.20-0.18-0.28-0.15-0.28-0.03-0.27-0.26-0.20-17.97-0.24-3.59-3.48-14.40-3.54-2.89-2.13-7.68-1.10
Shares Outstanding (Weighted Average) (Quarter)
30.06M100.60M135.92M244.18M246.31M248.32M247.08M249.59M249.90M251.32M12.55M254.25M12.74M12.77M13.07M14.76M14.77M15.95M17.09M21.88M
Shares Outstanding (Diluted Average) (Quarter)
30.06M239.38M135.92M244.18M245.25M246.28M247.08M249.59M249.90M251.32M12.55M254.25M12.74M12.81M13.07M14.76M14.79M18.27M17.09M21.88M
EBITDA (Quarter)
-62.69M-49.01M-85.26M-73.12M-38.07M-71.90M-6.00M-63.24M-62.39M-49.66M-51.84M-60.98M-45.80M-43.43M-192.40M-52.33M-42.78M-38.70M-140.68M-24.40M
Shares Outstanding (Quarter)
238.55M239.79M242.74M245.42M247.11M249.24M12.48M249.61M251.03M251.87M12.70M12.75M12.80M12.83M14.74M14.76M14.83M19.29M21.25M23.33M